logo-loader
viewValeo Pharma Inc.

Valeo Pharma receives Health Canada approval for commercialization for Amikacin

Valeo Pharma (CSE: VPH- OTCQB: VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive with news the company has received a Notice of Compliance from Health Canada granting market authorization for Amikacin. That drug is an antibiotic mostly used in hospitals.

Saviuk also told Proactive the company has also announced that shipments of Ethacrynate Sodium have commenced in the U.S. market. That is their first ever product launch in the United States.

Quick facts: Valeo Pharma Inc.

Price: 1.43 CAD

CSE:VPH
Market: CSE
Market Cap: $83.04 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics remain optimistic about US commercialisation of Accrufer...

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update. Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year. He...

2 days, 8 hours ago

2 min read